NCT06126666 - A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

November 15, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

ABL103

ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.

Trial Locations (3)

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam

03080

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Sevrance Hospital, Seoul